Reported results
- Collaboration and license revenue was $10.0 million for the quarter ended September 30, 2026, compared to $19.1 million for the quarter ended September 30, 2025.
- Research & development (R&D) expenses were $14.8 million for the quarter ended September 30, 2026, compared to $14.3 million for the quarter ended September 30, 2025.
- General & administrative (G&A) expenses were $6.9 million for the quarter ended September 30, 2026, compared to $6.7 million for the quarter ended September 30, 2025.
- Net loss was $5.9 million (or $0.30 per basic and diluted share) for the quarter ended September 30, 2026, compared to $16.3 million (or $1.58 per basic and diluted share) for the quarter ended September 30, 2025.
- Cash and cash equivalents were $122.2 million as of September 30, 2026, compared to $137.5 million as of December 31, 2025.
Guidance
- Xilio anticipates that its existing cash and cash equivalents will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2028.
- This estimate excludes up to $36.2 million in additional gross proceeds in the fourth quarter of 2026 if all outstanding Series C warrants are exercised at their current exercise price and up to $31.0 million in near-term milestones and option extension fees that could be achieved under the AbbVie collaboration through the first half of 2027.
- Xilio plans to report initial Phase 1 data for XTX501 in patients with metastatic NSCLC in the fourth quarter of 2027.
- Xilio plans to submit investigational new drug (IND) applications for XTX602 and XTX701 in the fourth quarter of 2027.
Notes
On March 13, 2026, the company effected a 1-for-14 reverse stock split of its common stock. All share amounts and per share amounts in the press release have been adjusted retroactively to reflect the reverse stock split for the periods presented.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.
